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Novel Norovirus 
 GII.4 Variant, 
Shanghai, China, 
2012
To the Editor: Norovirus (NoV) 
has been identified as one of the major 
causal agents of nonbacterial, acute 
gastroenteritis in humans (1). The ge-
netic diversity among NoVs is great, 
and human strains have been classified 
into 3 genogroups (GI, GII, and GIV). 
Despite this diversity, in recent years 
only a few strains, primarily those 
of genogroup II, genotype 4 (GII.4), 
have been responsible for most cases 
and outbreaks worldwide (1,2).
The pattern of epochal evolution 
of NoV is ongoing, and novel GII.4 
variants emerge, which replace pre-
viously dominant strains and cause 
new pandemics. Surveillance systems 
worldwide showed an increase in NoV 
activity in late 2012 (3). Molecular 
data shared through NoroNet (www.
rivm.nl/en/Topics/Topics/N/NoroNet) 
suggest that this increase is related to 
the emergence of a new GII.4 vari-
ant, termed Sydney_2012 (3). We 
found that this novel GII.4 variant 
also emerged in Shanghai, China, and 
caused increased levels of NoV activ-
ity during October–December 2012.
During July 2011–December 
2012, fecal specimens from 748 out-
patients (>16 years of age) with acute 
gastroenteritis who visited 1 of the 2 
sentinel hospitals in Shanghai were 
collected and stored at Shanghai Pub-
lic Health Clinical Center at −70°C. 
Molecular detection of GI and GII 
NoV was performed by using con-
ventional reverse transcription PCR 
as described (4). Full-length viral 
protein 1 and 639 bp of the 3′ RNA-
dependent RNA polymerase gene of 4 
randomly selected GII-positive strains 
were amplified (5–7). NoV genotypes 
were classified on the basis of a 280-
bp region for GI and a 305-bp region 
for GII by using the Automated Ge-
notyping Tool (www.rivm.nl/mpf/ 
norovirus/typingtool).
A total of 77 patients showed 
positive results for GII NoV. An in-
crease in GII NoV activity was ob-
served during October–December in 
2012; the detection rate was 46.08% 
(47 cases in 102 outpatients). The 
prevalence of GII NoV during the 
same period in 2011 was low; the de-
tection rate was 6.90% (8 cases in 116 
outpatients). Genotyping analysis of 
the strains detected in these 3 months 
in 2012 (39 strains were sequenced) 
showed that except for 1 GII.6 strain 
and 3 GII.4 2006b strains, the other 
35 strains sequenced all belong to 
the new established cluster of GII.4, 
termed Sydney_2012. Retrospective 
analysis indicated that the novel GII.4 
variant had already been detected in 2 
outpatients during September 2011 in 
Shanghai.
Phylogenetic analysis of full-
length capsid nucleotide sequences 
for 4 strains randomly selected from 
the new cluster indicated a novel 
GII.4 pattern, and new strains clus-
tering separately from previously 
identified GII.4 pandemic strains 
(Figure). On the basis of BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.
cgi) searches, the most closely re-
lated NoVs (98%–100% nucleotide 
identity) were 4 GII.4 viruses re-
cently detected in Australia and Hong 
Kong. The new GII.4 strains detected 
in Shanghai also clustered with these 
strains, a finding that was supported 
by bootstrap values >70% (Figure). 
The 3′ end of RNA-dependent RNA 
polymerase gene sequences also 
confirmed that the new GII.4 strains 
were recombinants, with a GII.e poly-
merase and GII.4 capsid (3).
Despite improved control mea-
sures to combat NOV, this highly infec-
tious agent continues to cause a large 
number of epidemics of gastroenteritis 
globally (approximately every 2 years), 
and most epidemics have been associ-
ated with emergence of a novel GII.4 
cluster (9). The new cluster reported 
in the present study was first detected 
in Australia in March, 2012, followed 
by detection in France, New Zealand, 
Japan, the United Kingdom, the Unit-
ed States, and Hong Kong, where in-
creased levels of NoV activity in late 
2012 compared with previous seasons 
were also observed (3). This novel 
GII.4 strain has also emerged in Shang-
hai, China, and caused increased levels 
of sporadic cases during October–and 
December 2012. This new variant has 
common ancestors, dominant NoV 
GII.4 variants Osaka_2007 and New 
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Orleans_2009, but is phylogenetically 
distinct from them. Amino acid chang-
es are present in major epitopes located 
in the P2 domain, a finding that is con-
sistent with observations from previous 
epidemics (3).
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To the Editor: Globally, antimi-
crobial drug resistance is rapidly ris-
ing, with resultant increased illness 
and death. Of particular concern is 
Escherichia coli, the most common 
bacterium to cause invasive disease 
in humans (1). In Europe, increasing 
proportions of bloodstream infections 
caused by E. coli are resistant to third-
generation cephalosporins (1,2).
Resistant E. coli can be transmit-
ted to humans from animals. A large 
proportion of resistant isolates caus-
ing human infections are derived from 
food animals (3–6). However, lack of 
data has made it difficult to quantify the 
proportion of antimicrobial drug resis-
tant E. coli infecting persons through 
food sources and the resultant effects 
on human health. Recent data from the 
Netherlands now make such estimates 
possible (2,6). The additional illness 
and death among humans resulting 
from bloodstream infections caused by 
third-generation cephalosporin–resis-
tant E. coli (G3CREC) has been cal-
culated for Europe (2). In the Nether-
lands, there were 205 G3CREC cases 
during 2007 (4% of all E. coli blood-
stream infections) (2). Another study 
in the Netherlands revealed that 56% 
of the resistance genes in G3CREC 
in humans were identical to genes de-
rived from E. coli isolated from retail 
chicken samples (6). Using the find-
ings of Overdevest et al. (6) and de 
Kraker et al. (2), we calculated that, in 
the Netherlands, infections in humans 
with G3CREC derived from poultry 
sources were associated with 21 addi-
tional deaths. G3CREC-related illness 
also resulted in 908 hospital bed-days 
needed to treat persons with these an-
timicrobial drug resistant bloodstream 
infections. If these values were extrap-
olated to all of Europe (i.e., if 56% of 
G3CREC were derived from poultry), 
1,518 additional deaths and an associ-
ated increase of 67,236 days of hospi-
tal admissions would be counted as a 
result of cephalosporin and other anti-
microbial drug use in poultry.
To more accurately estimate the 
associated increased deaths among per-
sons resulting from third-generation 
cephalosporin use in poultry, detailed 
data from more countries is essential. 
Needed data include records of antimi-
crobial drug use and resistant bacterial 
strains found in food animals and do-
mestic and imported foods. However, 
we already know that G3CREC is 
rapidly rising in many countries, and 
in Europe, the infection rate is likely 
to have tripled from 2007 to 2012 (2). 
Globally, billions of chickens receive 
third-generation cephalosporins in ovo 
or as day-old chicks to treat E. coli in-
fection, a practice that has resulted in 
large reservoirs of resistant bacteria. 
In Canada, this practice has been as-
sociated with substantial increases in 
resistance to third-generation cepha-
losporins in Salmonella enterica se-
rovar Heidelberg isolates detected in 
humans. (7). The United States Food 
and Drug Administration recently pro-
hibited the off-label use of cephalo-
sporins, including prophylactic uses, 
in major food animal species, includ-
ing poultry (8).
The number of avoidable deaths 
and the costs of health care potentially 
caused by third-generation cepha-
losporin use in food animals is stag-
gering. Considering those factors, the 
ongoing use of these antimicrobial 
drugs in mass therapy and prophy-
laxis should be urgently examined and 
stopped, particularly in poultry, not 
only in Europe, but worldwide.
Peter Collignon,  
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